Avalglucosidase alfa-ngpt 100 MG Injection — RxCUI 2565818
RxNorm drug concept · Semantic clinical drug
RxCUI 2565818
Semantic clinical drug · SCD
● Current RxNorm concept 1 FDA product
1 package NDC
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2565818
Official nameAvalglucosidase alfa-ngpt 100 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped1
Package NDCs mapped1
Reported Medicaid activity (SDUD)545 prescriptions · 15 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
🕸️ Concept Web — How Avalglucosidase alfa-ngpt 100 MG Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Avalglucosidase alfa-ngpt 100 MG Injection
RxCUI 2565818 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Avalglucosidase alfa
2565814IN -
Avalglucosidase alfa-ngpt
2565813PIN
-
Avalglucosidase alfa
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Nexviazyme
2565819BN
-
Nexviazyme
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Avalglucosidase alfa Injection
2565817SCDF -
Avalglucosidase alfa-ngpt Injection
2649202SCDFP -
Avalglucosidase alfa Injectable Product
2565816SCDG -
Avalglucosidase alfa-ngpt Injectable Product
2661900SCDGP -
Avalglucosidase alfa Injection [Nexviazyme]
2565822SBDF -
Avalglucosidase alfa-ngpt Injection [Nexviazyme]
2657406SBDFP -
Nexviazyme Injectable Product
2565821SBDG -
Injection
1649574DF - +1 more in this family
-
Avalglucosidase alfa Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Avalglucosidase alfa-ngpt 100 MG
2565815SCDC -
Avalglucosidase alfa-ngpt 100 MG Injection [Nexviazyme]
2565823SBD -
Avalglucosidase alfa-ngpt 100 MG [Nexviazyme]
2565820SBDC
-
Avalglucosidase alfa-ngpt 100 MG
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Avalglucosidase alfa-ngpt 100 MG
SCDC · 2565815 -
Avalglucosidase alfa Injection
SCDF · 2565817 -
Avalglucosidase alfa-ngpt Injection
SCDFP · 2649202 -
Avalglucosidase alfa Injectable Product
SCDG · 2565816 -
Avalglucosidase alfa-ngpt Injectable Product
SCDGP · 2661900
Brand-Name Concepts
-
Avalglucosidase alfa-ngpt 100 MG Injection [Nexviazyme]
SBD · 2565823 -
Avalglucosidase alfa-ngpt 100 MG [Nexviazyme]
SBDC · 2565820 -
Avalglucosidase alfa Injection [Nexviazyme]
SBDF · 2565822 -
Avalglucosidase alfa-ngpt Injection [Nexviazyme]
SBDFP · 2657406 -
Nexviazyme Injectable Product
SBDG · 2565821 -
Nexviazyme
BN · 2565819
📦 FDA Products & Package NDCs
1 product · 1 package NDC
1 package NDC map to RxCUI 2565818 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 58468-0426-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (58468-0426-1) / 10 mL in 1... | Nexviazyme | Genzyme Corporation | 2021-08-06 |
Observed labelers:
Genzyme Corporation (1)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J0219 | Inj aval alfa-nqpt 4mg | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.